Tuberculosis and HIV infection: How to safely treat both disorders concurrently

Postgraduate Medicine

Volumn 108, Issue 2, 2000, Pages 57-68

  Decker, Catherine F ^a   Lazarus, Angeline ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; ETHAMBUTOL; INDINAVIR; ISONIAZID; NELFINAVIR; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STREPTOMYCIN SULFATE; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

CLINICAL FEATURE; CLINICAL PROTOCOL; CONFERENCE PAPER; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENCE; PATHOGENESIS; RISK FACTOR; TREATMENT INDICATION; TREATMENT PLANNING; TUBERCULIN TEST; TUBERCULOSIS;

EID: 0033844329     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.2000.08.1181     Document Type: Conference Paper

References (22)

1. Tuberculosis - United States, 1985 - And the possible impact of human T-lymphotropic virus type III/lymphadenopathy-associated virus infection
2. Tuberculosis morbidity - United States, 1996
3. Tuberculosis in patients with human immunodeficiency virus infection
4. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: Principles of therapy and revised recommendations
5. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection
6. Epidemiology of extra-pulmonary tuberculosis among persons with AIDS in the United States
7. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: An analysis using restriction-fragment-length polymorphisms
8. The impact of human immunodeficiency virus infection on drug-resistant tuberculosis
9. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis
10. Role of the mononuclear phagocyte system in the immunopathogenesis of human immunodeficiency virus infection and the acquired immunodeficiency syndrome
11. Copathogenicity of tuberculosis and human immunodeficiency virus disease
12. Isoniazid preventive therapy in human immunodeficiency virus-infected persons: Long-term effect on development of tuberculosis and survival
13. Tuberculosis in patients with the acquired immunodeficiency syndrome: Clinical features, response to therapy, and survival
14. Frequency of Mycobacterium tuberculosis bacteremia in patients with tuberculosis in an area endemic for AIDS
15. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS
16. The utility of a single sputum specimen in the diagnosis of tuberculosis: Comparison between HIV-infected and non-HIV-infected patients
17. Comparison of the amplified Mycobacterium tuberculosis (MTB) direct test, amplicor MTB PCR, and IS6110-PCR for detection of MTB in respiratory specimens
18. Factors influencing time to sputum conversion among patients with smear-positive pulmonary tuberculosis
19. Drug interactions in patients infected with human immunodeficiency virus
20. The emergence of drug-resistant tuberculosis in New York City
21. Treatment of multidrug-resistant tuberculosis
22. Tuberculosis and human immunodeficiency virus infection: Recommendations of the Advisory Committee for the Elimination of Tuberculosis (ACET)